| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President and CEO | President and CEO | Director, Senior Advisor +1 more
1 company
Christopher Posner last filed a Form 4 in February 2025, as President and CEO at TVRD. Christopher Posner's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Christopher Posner's trades have earned a strong insider score of 80/100 across 16 rated trades. Over a 12-month horizon, 93.8% of those trades were profitable, with an average 12-month return of +51.8%.
At the last filing, the largest reported position was 13,109 shares of TVRD. The TVRD filings lean toward selling, a net 102,028 shares.
Christopher Posner has 23 Form 4 filings on record from August 2018 to February 2025, all as President and CEO at Tvardi Therapeutics (TVRD), 2018–2025.
The 31 reported transactions were 17 open-market sales, 7 stock awards and 7 option or other derivative awards.
Counted by filing, the open-market trades come to no purchases and 17 sales worth about $427K.
The largest open-market sale was 14,470 shares of TVRD at an average $11.13 on November 16, 2022, about $161K. Twelve months later TVRD was down 90%.
2 of the 11 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 9 were not.
Shares as reported in the last Form 4 for each company; the most recent is from February 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 28, 2025 | TVRD Tvardi Therapeutics, Inc. | President and CEO | Sell | 583 | $4.75 | $2,769.25 | -4.3% | +108.2% | -72.2% | |
| Feb 4, 2025 | TVRD Tvardi Therapeutics, Inc. | President and CEO | Sell | 372 | $4.72 | $1,755.84 | -2.6% | +88.7% | -73.8% | |
| Nov 4, 2024 | TVRD Tvardi Therapeutics, Inc. | President and CEO | Sell | 3,668 | $0.29 | $1,063.72 | -2.1% | +36.5% | -58.2% | |
| Aug 1, 2024 | TVRD Tvardi Therapeutics, Inc. | President and CEO | Sell | 4,149 | $0.35 | $1,452.15 | -2.3% | -18.5% | +105.1% | |
| May 2, 2024 | TVRD Tvardi Therapeutics, Inc. | President and CEO | Sell | 3,936 | $0.75 | $2,952.00 | -2.2% | -54.9% | -3.8% | |
| Feb 29, 2024 | TVRD Tvardi Therapeutics, Inc. | President and CEO | Sell | 5,834 | $0.89 | $5,192.26 | -3.1% | -27.4% | -53.1% | |
| Feb 8, 2024 | TVRD Tvardi Therapeutics, Inc. | President and CEO | Sell | 35,575 | $0.53 | $18,854.75 | -16.0% | +41.0% | -19.9% | |
| Feb 1, 2024 | TVRD Tvardi Therapeutics, Inc. | President and CEO | Sell | 4,981 | $0.55 | $2,739.55 | -2.2% | +35.2% | -28.1% | |
| Nov 2, 2023 | TVRD Tvardi Therapeutics, Inc. | President and CEO | Sell | 3,796 | $1.22 | $4,631.12 | -2.3% | -52.5% | -75.0% | |
| Aug 3, 2023 | TVRD Tvardi Therapeutics, Inc. | President and CEO | Sell10b5-1 | 4,307 | $3.07 | $13,222.49 | -2.5% | -62.1% | -89.2% |